source
- Merck halts development of BTK inhibitor acquired in $2.7 billion ArQule purchaseMerck announced it is stopping work on nemtabrutinib, a Bruton's tyrosine kinase (BTK) inhibitor. The drug was the primary asset that motivated Merck’s 2019 acquisition of ArQule for $2.7 billion.…
- Biogen's low-dose tau drug shows greater slowing of Alzheimer’s progression after two yearsBiogen reported new data on its experimental tau-reducing therapy diranersen, showing that the lowest dose continued to slow Alzheimer’s disease progression after nearly two years of treatment. Th…